Celsis International, a UK-based provider of microbial detection systems and services, said last week that it will use microarray technology developed by BioVentures in its next generation of contamination tests.

The agreement marks the first time Celsis will use a microarray-based platform for its tests, as well as the first commercialization partner for BioVenture's technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.